US20150283321A1 - Priming detection system and method of using the same - Google Patents

Priming detection system and method of using the same Download PDF

Info

Publication number
US20150283321A1
US20150283321A1 US14/246,982 US201414246982A US2015283321A1 US 20150283321 A1 US20150283321 A1 US 20150283321A1 US 201414246982 A US201414246982 A US 201414246982A US 2015283321 A1 US2015283321 A1 US 2015283321A1
Authority
US
United States
Prior art keywords
fluid
delivery
infusion system
infusion
reactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US14/246,982
Other versions
US9707336B2 (en
Inventor
Kiem H. Dang
Edgardo C. Halili
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Minimed Inc
Original Assignee
Medtronic Minimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Minimed Inc filed Critical Medtronic Minimed Inc
Priority to US14/246,982 priority Critical patent/US9707336B2/en
Assigned to MEDTRONIC MINIMED, INC. reassignment MEDTRONIC MINIMED, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DANG, KIEM H., HALILI, EDGARDO C.
Publication of US20150283321A1 publication Critical patent/US20150283321A1/en
Application granted granted Critical
Publication of US9707336B2 publication Critical patent/US9707336B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142Pressure infusion, e.g. using pumps
    • A61M5/14244Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/162Needle sets, i.e. connections by puncture between reservoir and tube ; Connections between reservoir and tube
    • A61M5/1626Needle protectors therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01DMEASURING NOT SPECIALLY ADAPTED FOR A SPECIFIC VARIABLE; ARRANGEMENTS FOR MEASURING TWO OR MORE VARIABLES NOT COVERED IN A SINGLE OTHER SUBCLASS; TARIFF METERING APPARATUS; MEASURING OR TESTING NOT OTHERWISE PROVIDED FOR
    • G01D7/00Indicating measured values
    • G01D7/005Indication of measured value by colour change
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M2005/1401Functional features
    • A61M2005/1402Priming
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00General characteristics of the apparatus
    • A61M2205/58Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583Means for facilitating use, e.g. by people with impaired vision by visual feedback

Definitions

  • This invention relates to a fluid infusion system having a priming detection system, and in particular embodiments, one or more components of a fluid infusion system having a reactive element that provides a color change upon contact with an infusion fluid to indicate the completion of priming of the infusion system.
  • Continuous subcutaneous infusion of medications is a prevalent method of drug delivery.
  • an individual uses a small programmable pump to deliver medication through a flexible plastic tube to an infusion set.
  • the infusion set delivers medication to an individual's subcutaneous tissue through the use of either a rigid needle that is left in the tissue or through a flexible cannula that remains in the tissue after being inserted via a removable needle.
  • the most common infused fluid is insulin.
  • other infused fluids include HIV drugs, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, and anti-cancer treatments.
  • An insulin delivery system generally includes a pump, tubing and infusion set attached to a cannula or needle.
  • the tubing is connected to the pump at one end and connected to the cannula or needle at the other end to deliver the insulin into the body.
  • the user executes a priming sequence to fill the tubing and cannula or needle with insulin prior to insertion of the cannula or needle into the body.
  • infusion systems can include a needle guard to cover the needle and prevent accidental poking of oneself. Such systems require removal of the needle guard to allow the user to view the insulin droplet form at the tip of the needle during the priming sequence of the pump.
  • Current infusion systems do not provide a noticeably clear method to observe completion of priming without straining the eyesight and/or compromising the safety of the user.
  • Embodiments of the present invention include a priming detection system and method for clear visual confirmation that a component of an infusion system is primed with an infusion fluid, which obviate for practical purposes, the above mentioned limitations.
  • the infusion system includes at least one reactive element to react with a fluid to be delivered into an individual's body.
  • the reactive element reacts with the fluid or a component within the fluid when the fluid contacts the reactive element to produce a color change.
  • the color change indicates that the component of the infusion system is primed with the fluid.
  • the delivered fluid can be a therapeutic agent such as insulin or any other suitable medicament.
  • the system can further include a delivery element, such as a cannula or needle.
  • the delivery element can have a proximal end and a distal end.
  • the distal end of the delivery element can be configured to penetrate the individual's body and the proximal end of the delivery element can be directly or indirectly connected to the delivery device, to provide fluid communication between the delivery device and the individual's body so that the fluid can travel from the delivery device through the delivery element into the individual's body.
  • the reactive element is deposited on or incorporated in at least a portion of the delivery element.
  • the system further includes a guard element to at least partially surround or cover at least a portion of the delivery element.
  • the guard element includes at least one reactive element that reacts with the fluid exiting from the delivery element to produce a color change to indicate that the delivery element is primed with the fluid.
  • the guard element has an interior surface and an exterior surface and the reactive element is deposited on at least a portion of the interior surface of the guard element.
  • the reactive element can be incorporated into the material comprising the guard element.
  • the infusion system further includes a device for delivering the fluid into the individual's body.
  • the delivery device can be an infusion pump, an infusion set, or another suitable fluid delivery device or fluid source.
  • the infusion pump is coupled to the delivery element.
  • the infusion set is coupled to the delivery element.
  • the system can include a tube coupled between an infusion set and an infusion pump, and/or between the delivery element and the delivery device, such as an infusion set or infusion pump.
  • at least one reactive element can be deposited within at least a portion of the tube.
  • At least one reactive element can be applied to or incorporated in one or more components of the infusion system.
  • at least one reactive element is encapsulated in micro-spheres.
  • at least one reactive element is a component of a coating.
  • the invention is a fluid detection system having at least one reactive element to indicate a component of an infusion system is primed with a fluid to be delivered into an individual's body.
  • the fluid detection system comprises a delivery element having a proximal end and a distal end, the distal end configured to penetrate the individual's body and the proximal end coupled to a fluid source.
  • the fluid source can be an infusion set and/or an infusion pump.
  • the fluid detection system further includes a guard element having a body that surrounds at least a portion of the delivery element. The guard element includes at least one reactive element that reacts with the fluid exiting from the distal end of the delivery element to produce a color change to indicate that the delivery element is primed with the fluid.
  • At least one reactive element is a liquid-activated dye to produce the color change when the fluid contacts the dye.
  • the liquid activated dye is a reversible or irreversible hydrochromatic or hydrochromic ink or dye.
  • at least one reactive element includes a chemical that reacts with at least one component within the fluid to produce the color change.
  • at least one reactive element contains at least 4-amino-antipyrine and potassium ferricyanide.
  • at least one reactive element contains at least 4-amino-antipyrine, potassium ferricyanide and horse radish peroxidase (HRP).
  • at least one reactive element contains at least ninhydrin.
  • at least one reactive element contains at least Coomassie Brilliant Blue.
  • at least one reactive element contains dithizone.
  • the method comprises: providing the fluid and a device for delivering the fluid into the individual's body; providing the delivery element having a proximal end and a distal end, the distal end configured to penetrate the individual's body and the proximal end connected to the delivery device; providing a guard element to cover at least the distal end of the delivery element; depositing at least one reactive element that reacts with the fluid on the guard element; and producing and/or observing a color change when the fluid exiting from the distal end of the delivery element reacts with at least one reactive element on the guard element.
  • the color change indicates that the delivery element is primed with the fluid.
  • FIG. 1 is a diagram showing an infusion set attached to a body, a flexible tube, and an infusion pump according to an embodiment of the present invention.
  • FIG. 2 is a perspective view of an infusion system according to an embodiment of the present invention.
  • FIG. 3A is a cross-sectional side view of an infusion set attached to a body tissue according to an embodiment of the present invention.
  • FIG. 3B is a perspective bottom view of the infusion set of FIG. 3A according to an embodiment of the present invention.
  • FIG. 3C is an enlarged front perspective view of a distal end of a delivery element having at least one reactive element deposited on at least a portion of the interior surface of the delivery element according to an embodiment of the present invention.
  • FIG. 3D is an enlarged front perspective view of a distal end of a delivery element having at least one reactive element deposited on at least a portion of the exterior surface of the delivery element according to an embodiment of the present invention.
  • FIG. 4 is a side view of an infusion pump attached to a body tissue, with a partial cut away of the pump, showing a cross-sectional view of a delivery element penetrating the body tissue according to an embodiment of the present invention.
  • FIG. 5 is a perspective bottom view of an infusion set and a perspective view of a guard element according to an embodiment of the present invention.
  • FIG. 6 is a perspective bottom view of an infusion set and a perspective view of a guard element covering a delivery element according to an embodiment of the present invention.
  • FIG. 7 is a perspective bottom view of an infusion set and a perspective view of a guard element covering a delivery element and showing a color change to indicate the delivery element is primed according to an embodiment of the present invention.
  • FIG. 8 is a perspective side view of a guard element having at least one reactive element deposited on the interior surface of the guard element according to an embodiment of the present invention.
  • FIG. 9 is a front view of an open end of a guard element having at least one reactive element deposited on at least a portion of the interior surface of the guard element according to an embodiment of the present invention.
  • FIG. 10 is a front view of an open end of a guard element having at least one reactive element incorporated in at least a portion of the guard element according to an embodiment of the present invention.
  • FIG. 11 is a perspective bottom view of an infusion set and a perspective view of a guard element surrounding a delivery element according to an embodiment of the present invention.
  • FIG. 12 is a perspective side view of a guard element having at least one reactive element deposited on the interior surface of the guard element according to an embodiment of the present invention.
  • FIG. 13 is a perspective bottom view of an infusion set and is a perspective view of a guard element surrounding a delivery element and showing a color change to indicate the delivery element is primed according to an embodiment of the present invention.
  • FIG. 14 is a diagram of a phenol molecule.
  • FIG. 15 is a diagram of a benzyl alcohol molecule.
  • FIG. 16 is a diagram of a 4-amino-antipyrine molecule.
  • FIG. 17 is a diagram of a potassium ferricyanide (K3Fe(CN)6 molecule.
  • FIG. 18 is a diagram of a bright blue chemical complex.
  • FIG. 19 is a diagram of a dithizone molecule.
  • the invention is embodied in an infusion system having a priming detection system designed to indicate the presence of a fluid that has been primed through a fluid path of the infusion system for delivery of the fluid into an individual's body at an infusion site.
  • the priming detection system includes at least one reactive element that reacts with the fluid or a component of the fluid to produce a color change.
  • the provided color change is a clear indication that a component of the infusion system has been primed with the infusion fluid and is ready for use.
  • the infused fluid can be any therapeutic agent. In preferred embodiments the infused fluid is insulin.
  • fluids may be administered through infusion such as, but not limited to, HIV drugs, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, anti-cancer treatments, vitamins, hormones, or the like.
  • Preferred embodiments are for use with human beings; however, alternative embodiments may be used with animals or fluid flow applications where detection of small amounts of primed fluid is important.
  • An infusion system 10 utilizing the priming detection method can include any or all of the components shown in FIG. 1 .
  • An infusion pump 36 regulates the flow of fluid into an individual's body.
  • the fluid flows from an infusion pump 36 , through a flexible tube 40 , through a delivery device such as, an infusion set 38 , or the like, and through a delivery element (not shown) that is adhered to the individual's body 16 .
  • Infusion sets 38 that may be used as a delivery device are described in, but not limited to, U.S. Pat. Nos. 5,176,662; 5,257,980; 5,584,813; 6,056,718; and 6,461,329, which are hereby incorporated by reference.
  • the infusion pump 36 may be of the type described in U.S. Pat. No. 4,562,751; 4,685,903; 5,080,653; 5,097,122; 5,505,709; 6,248,093; 6,554,798; and 6,752,785, which are hereby incorporated by reference.
  • other infusion pumps 36 may be used for delivery of fluid 14 through an infusion set 38 or through a delivery element to an individual's body 16 .
  • the infusion pump 36 comprises a relatively compact pump housing 54 defining an elongated reservoir compartment 56 adapted to receive a reservoir 58 filled with a selected fluid, such as medication to be administered to an individual.
  • the reservoir 58 may be a fillable or pre-filled reservoir, cartridge, syringe or the like.
  • the reservoir 58 includes a barrel 60 for containing the fluid 14 .
  • a connector 66 serves as the interface between the reservoir 58 and the tube 40 .
  • the infusion pump 36 can include electronics and a motor to control movement of a plunger 62 for advancing the reservoir 58 to deliver the fluid 14 through a flexible tube 40 or the like into an individual's body.
  • the fluid 14 flows along a normal fluid path from reservoir 58 seated within the infusion pump 36 , through the flexible tube 40 , through a delivery device, such as the infusion set 38 or the like, and exits through a delivery element 20 , such as a cannula, hollow needle, capillary, conduit, lumen, or the like, to deliver the fluid 14 to an infusion site 12 .
  • the infusion site 12 is at a location where a delivery element 20 penetrates an individual's body.
  • one end of the delivery element 20 is attached to a delivery device and the other end, once primed with the infusion fluid 14 , is inserted through an individual's skin 74 terminating in an individual's subcutaneous tissue 76 or another tissue such as, muscle, organ, inter-peritoneal, intra-peritoneal, or the like.
  • the delivery element 20 establishes fluid communication between the delivery device and the individual's body.
  • the delivery device is an infusion set 38 coupled to the delivery element 20 .
  • the delivery device can be an infusion pump 36 or other fluid source directly attached to the surface of the individual's skin 74 and having a delivery element 20 .
  • the delivery element 20 directs the fluid 14 from a cavity 72 inside the infusion set 38 , through the individual's skin, and into the individual's subcutaneous tissue 76 .
  • the characteristics of delivery element 20 such as the length, inner and outer diameter, end configurations, and materials may vary depending on the tissue type that the delivery element 20 is inserted into, the volume and type of fluid 14 being infused, the configuration of the delivery device, and other parameters.
  • the delivery element 20 can include a proximal end 22 and a distal end 24 .
  • the distal end 24 is configured to penetrate the individual's body and the proximal end 22 is connected or coupled to the delivery device, thus providing fluid communication between the delivery device and the individual's body.
  • a tube 40 may be included to connect the infusion set 38 to the infusion pump 36 or other fluid source (not shown).
  • the delivery device is an infusion pump 36 adhered directly to the individual's skin 74 .
  • the infusion pump 36 has a cannula as the delivery element 20 , to deliver fluid 14 directly from the infusion pump 36 through the individual's skin 74 to the subcutaneous tissue 76 .
  • other fluid conducting delivery elements 20 are used such as capillaries, conduits, lumens, or the like.
  • the infusion pump 36 may be of the type described in U.S. Pat. Nos.
  • the infusion pump 36 or infusion set 38 includes one or more pads 68 to attach the delivery device to the individual's skin 74 .
  • the pads 68 include an adhesive, and the pad 68 may be made of an adhesive, foam, glue, tape, a material coated with adhesive, or the like.
  • one side of the pad 68 can be attached to a base 70 of a delivery device, while the opposite side of the pad 68 can be adhered to an individual's skin 74 .
  • the delivery device is held to the individual's skin 74 with a tape.
  • both the adhesive of the pad 68 and tape are used to secure the infusion pump 36 or infusion set 38 to the individual's skin 74 .
  • a guard element 30 is included in the infusion system 10 and is configured to at least partially surround or cover at least a portion any of the above-described delivery elements 20 , preferably the distal end of a delivery element 20 .
  • the guard element 30 can be a needle guard, cap, lid, top, cover, or the like.
  • the guard element 30 can have a first end 31 and a second end 33 . In embodiments, at least one of the first end 31 and second end 33 of the guard element 30 can connect to the delivery device having the delivery element 20 .
  • the guard element 30 and delivery device such as an infusion set can have mating or interfitting parts such as male and female threaded or snapping counterparts or the like to connect the guard element 30 to the delivery device.
  • the guard element 30 comprises an elongated body 46 having a first end 31 that is an open end 50 to accept the delivery element 20 and a second end 33 that is a closed end 48 to enclose at least a portion of the delivery element 20 .
  • the guard element 30 can be made of a plastic or polymeric material, non-fiber material, fiber material or the like.
  • the guard element 30 can be made of a rigid material to shield the user from the sharp distal end of a delivery element 20 , such as a needle, and to further block contaminants from reaching the delivery element 20 to keep the delivery element 20 sterile.
  • the fluid detection portion of the infusion system 10 that indicates when a component of the infusion system 10 is primed includes at least one reactive element 26 that changes color upon contact with the fluid 14 to be delivered to the user's body.
  • the reactive element 26 or reactants may be deposited on the surfaces of the components, such as the guard element 30 , the delivery element 20 , the infusion set 38 , and/or the tube 40 , by different methods.
  • the reactive element 26 can be sprayed, coated, deposited, layered or screened directly onto at least a portion of the surface of one or more of the components.
  • the reactive element 26 can be encapsulated in micro-spheres or included as a component of a material such as a gel, an absorbent material, foam, porous materials, starch granules, or the like, which are applied to at least a portion of the surface of one or more of the components.
  • a material such as a gel, an absorbent material, foam, porous materials, starch granules, or the like, which are applied to at least a portion of the surface of one or more of the components.
  • the reactive element 26 can be embedded in or otherwise incorporated in at least a portion of one or more components of the infusion system 10 .
  • the reactive element 26 can be applied to or incorporated into fabric materials, non-fabric materials, plastic or polymeric materials, fibrous materials, foam, porous materials, or the like, or other materials that wick away fluid to accelerate the reaction or make the resulting product of the reaction more visible and easily observable to the user.
  • the reactive element can be embedded in pockets of such materials.
  • the reactive element 26 can be sprayed, coated, deposited, layered or screened onto a layer that is applied to at least a portion of the surface of one or more of the components.
  • the layer can be made of hydrogel, cloth, fibrous material, porous material, or other materials that wick away fluid to accelerate the reaction or make the resulting product of the reaction more visible.
  • a label of any suitable flexible material may be prepared with the reactants on one or both sides of the label, and the label may be applied onto a surface of the guard element 30 , the delivery element 20 , the infusion set 38 , and/or the tube 40 .
  • the guard element 30 covers the delivery element 20 such that the interior surface 32 of the guard element 30 faces the delivery element 20 .
  • the fluid 14 will exit the distal end of the delivery element 20 and come into contact with the guard element 30 covering the delivery element 20 , and thus come into contact with the reactive element 26 coated on or incorporated in at least a portion of the guard element 30 .
  • the reactive element 26 will produce a color change 28 that indicates that the system is primed through the delivery element 20 and is ready for insertion at the infusion site 12 .
  • the guard element 30 has an interior surface 32 and an exterior surface 34 , and the reactive element 26 is deposited or coated on a portion of or the entire interior surface 32 within the guard element 30 .
  • the reactive element 26 is deposited or coated in a layer that is applied to the interior surface 32 of the guard element 30 .
  • the reactive element 26 is incorporated into the body of the guard element 30 .
  • the guard element 30 can be made of a sintered plastic that absorbs liquid, a rigid fiber material, or other suitable material that can incorporate the reactive element 26 .
  • the reactive element 26 may be deposited on a wicking material incorporated in or deposited on the interior surface 32 of the guard element to make the color change 28 easier to observe by the user.
  • the wicking material may draw the leaking fluid 14 toward the exterior surface of the guard element.
  • the guard element 30 or other component of the system utilizing the reactive element, is clear or transparent to increase visibility of the color change 28 .
  • the guard element 30 or other component of the system utilizing the reactive element, may be comprised of a translucent material that allows color to be seen through the translucent material.
  • the guard element 30 can have a body 46 with a first end 31 and a second end 33 .
  • the first end 31 and second end 33 can comprise two open ends 50 and 50 ′.
  • the guard element 30 can surround the delivery element 20 and have a body 46 that extends past the delivery element 20 .
  • at least the first end 31 or the second end 33 of the guard element 30 can connect with a delivery device to surround the delivery element 20 .
  • one open end 50 ′ of the guard element 30 and a portion of the delivery device such as an infusion set to which the open end 50 ′ connects can have mating or interfitting parts 88 such as male and female threaded or snapping counterparts or the like to connect the guard element 30 to the delivery device.
  • the guard element 30 surrounds the delivery element 20 such that one end of the guard element 30 is attached to the delivery device and the interior surface 32 of the guard element 30 faces the delivery element 20 .
  • the reactive element 26 will produce a color change 28 that indicates that the system is primed through the delivery element 20 .
  • the user can then remove the guard element 30 from the delivery device, such as an infusion set 38 , for insertion of the delivery element 20 into an individual's body.
  • the reactive element 26 may be deposited on at least a portion of the interior surface 23 of the infusion set 38 or interior surface 25 of the tube 40 that are wetted by the fluid 14 when the fluid 14 flows along the normal fluid path of the system.
  • the reactive element 26 can be deposited on at least a portion of the delivery element 20 .
  • the reactive element 26 may be coated on an interior surface 27 of the delivery element 20 .
  • the entire interior surface 27 or a portion of the interior surface 27 of the delivery element 20 can be coated.
  • the reactive element 26 can be deposited at the exit on the edge of the distal end on the exterior surface 29 of the delivery element 20 , as shown in an embodiment in FIG.
  • Embodiments utilizing the reactive element 26 that contact the fluid 14 to be infused along a fluid flow path of the system can use one or more reactive elements 26 that are safe for use in the individual's body so as not to harm the individual.
  • the components utilizing the reactive element 26 will produce a color change 28 to indicate that the component is primed with the infusion fluid 14 .
  • the components of the system utilizing the color-changing reactive element may include other clear (optically transparent or translucent) materials for the individual to see through the component and observe the reaction.
  • the reactive element 26 can be a liquid-activated dye.
  • the dye or ink can reversibly and irreversibly change from a first color to a second color when exposed to water.
  • a fluid 14 or liquid for example water or a fluid containing water
  • the dye can change from a first color to a second color when wet and remain the second color when dry, or change back to the first color when dry.
  • the color can change from a dark color to a light color, a light color to a dark color, become transparent, or change from and to any color of the rainbow and shades in between, including white and black.
  • the liquid-activated dyes can be reversible or irreversible hydrochromatic or hydrochromic inks or coatings or the like.
  • the first and second colors can be adjusted based on the hydrochromatic or hydrochromic molecules used in the dyes that are known to persons having ordinary skill in the art.
  • the reactive dye can react with at least one component within the fluid 14 .
  • the fluid 14 to be delivered into an individual's body includes a protein, such as an insulin formulation
  • other reactive elements may be used to produce a color change 28 .
  • either ninhydrin or Coomassie Brilliant Blue reacts with the protein in the fluid 14 resulting in a brightly colored product.
  • Other color-changing chemicals or dyes specific to the infused fluid 14 or a known component of the infused fluid 14 such as a protein, hormone, or other like component, can be used.
  • the at least one reactive element 26 can be a colorimetric protein assay reagent or chemical that reacts with a component of the fluid 14 to be delivered.
  • the reagent can be a dye that binds to a protein or a portion of a protein complex such that the color change 28 is directly or indirectly associated with the bound dye.
  • the color change 28 in such embodiments can indicate the amount or strength of the protein in the fluid 14 .
  • the reactive element 20 includes a chemical that reacts with preservatives in the infusion fluid 14 to generate a highly visible, brightly colored, chemical complex.
  • Most fluids designed for parenteral administration (and/or infusion) contain a preservative.
  • the most commonly used preservatives are based either on a phenol system 78 or a benzyl alcohol system 80 . Examples of these systems are shown in FIGS. 14 and 15 respectively.
  • one approach to detecting the fluid is to trigger a chemical reaction that is observable by an individual when any of these preservatives are present in a fluid.
  • a material for example a clear gel, containing 4-amino-antipyrine 82 , shown in FIG. 16 , and potassium ferricyanide 84 (K3Fe(CN)6), shown in FIG. 17 , is deposited on at least a portion of the surface of a component of the system.
  • the preservative in the parenteral fluid reacts with the 4-amino-antipyrine 82 and potassium ferricyanide 84 in the material.
  • the resulting product is a bright blue colored complex 86 .
  • the reactive elements seen on, through, or around the edges of a component of the system, change from clear to bright blue, serving as a visual indicator to the individual.
  • a drawing of the structure of the resulting bright blue colored complex 86 is shown in FIG. 18 .
  • the time required for detection may vary due to the concentrations of the reactants, 4-amino-antipyrine 82 and potassium ferricyanide 84 , the concentration of the preservative in the fluid, the flow rate of the fluid, the rate at which the fluid comes in contact with the reactants, the method used to deposit the chemicals, the temperature, and the presence of contaminants.
  • the clear gel may be some other color, such as white, cream, off white, or the like, or a contrasting color to make the color change 28 noticeable.
  • the colored product is a different color, such as red, yellow, orange, pink, green, purple, or the like.
  • an enzymatic system is used to amplify the chemical color change 28 signal.
  • An enzyme such as horse radish peroxidase (HRP)
  • HRP horse radish peroxidase
  • a fluid 14 reaches the enzyme, water in the fluid 14 dissolves the HRP.
  • the HRP then acts as a catalyst to, in essence, create an enzymatic amplification of the signal.
  • a deep blue colored complex 86 is formed due to the phenol 78 or benzyl alcohol 80 preservatives in the fluid 14 reacting with 4-aminoantipyrine 82 and potassium ferricyanide 84 .
  • the advantage of the HRP system is that only very small amounts of the fluid 14 need to be present to be detected.
  • the time required to detect the fluid 14 can vary depending on the concentration of HRP present in the gel, the concentration of the reactants 4-aminoantipyrine 82 and potassium ferricyanide 84 , the method used to deposit the chemicals, the rate that the fluid 14 spreads and comes in contact with the reactants, the temperature, and the concentration of contaminates.
  • the catalysts described above, which amplify the color change 28 from the chemical reaction may also be deposited on a surface of a component of the system, such as the guard element 30 , tubing 40 , infusion set 38 , or delivery element 20 of the system 10 .
  • the reactive element 20 includes a chemical that reacts with zinc in an infusion fluid 14 to generate a color change.
  • a drawing of the structure of an example molecule, dithizone 90 is shown in FIG. 19 .
  • the infusion fluid 14 can be insulin.
  • Insulin formulations can include zinc that will react with the dithizone molecule 90 to produce a color change.
  • Dithizone 90 can be incorporated in or deposited, coated, or the like, on a component of the infusion system 10 to indicate the component is primed.
  • the reactive elements 20 such as dithizone 90 , 4-aminoantipyrine 82 and/or potassium ferricyanide 84 are encapsulated in micro-spheres.
  • the micro-spheres dissolve in the presence of an ingredient contained in the infused fluid 14 , such as water, alcohol, insulin or the like, which then sets the reactants free to react with the preservative in the fluid 14 as described above.
  • Additional embodiments include HRP encapsulated in micro-spheres along with 4-aminoantipyrine 82 and potassium ferricyanide 84 . In other embodiments, different methods are employed.
  • These methods include applying the reactive elements with starch granules, depositing them in pockets formed in a component of the system, such as the guard element 30 , encapsulating them and mixing them with a gel, embedding them into a component of the system, or the like.
  • the method comprises: providing the fluid and a device for delivering the fluid into the individual's body; providing the delivery element having a proximal end and a distal end, the distal end configured to penetrate the individual's body and the proximal end connected to the delivery device; providing a guard element to cover at least the distal end of the delivery element; depositing at least one reactive element that reacts with the fluid on the guard element; and producing and/or observing a color change when the fluid exiting from the distal end of the delivery element reacts with the at least one reactive element, thereby indicating that the delivery element is primed with the fluid.

Abstract

An infusion system having a priming detection system to indicate that a component of the system, for example a cannula or needle, is primed with a fluid to be delivered into an individual's body. The infusion system utilizes a reactive element that reacts with the fluid or at least one component of the fluid to be delivered, to produce a color change or a colored complex. The reactive element can be deposited, coated or otherwise incorporated in any component of the infusion system that would benefit from a visible indication of a primed fluid, including, but not limited to a tubing, infusion set, cannula, needle and/or guard element at least partially covering or surrounding a cannula or needle. The visual indication improves the user experience during the priming and filling of the system by providing a clear color change confirmation upon priming completion and prior to insertion into the body.

Description

    FIELD OF THE INVENTION
  • This invention relates to a fluid infusion system having a priming detection system, and in particular embodiments, one or more components of a fluid infusion system having a reactive element that provides a color change upon contact with an infusion fluid to indicate the completion of priming of the infusion system.
  • BACKGROUND OF THE INVENTION
  • Continuous subcutaneous infusion of medications is a prevalent method of drug delivery. Typically, an individual uses a small programmable pump to deliver medication through a flexible plastic tube to an infusion set. The infusion set delivers medication to an individual's subcutaneous tissue through the use of either a rigid needle that is left in the tissue or through a flexible cannula that remains in the tissue after being inserted via a removable needle. The most common infused fluid is insulin. An estimate of over 500,000 individuals worldwide use subcutaneous infusion of insulin for the treatment of diabetes mellitus. However, other infused fluids include HIV drugs, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, and anti-cancer treatments.
  • An insulin delivery system generally includes a pump, tubing and infusion set attached to a cannula or needle. The tubing is connected to the pump at one end and connected to the cannula or needle at the other end to deliver the insulin into the body. During the initial set up of the system, the user executes a priming sequence to fill the tubing and cannula or needle with insulin prior to insertion of the cannula or needle into the body.
  • Existing methods of detecting whether the tubing and cannula or needle is primed with insulin require the user to watch for droplets of insulin forming on the tip of the needle. This method of detection can be challenging for those who have poor vision, especially the elderly and diabetics with impaired vision. In addition, infusion systems can include a needle guard to cover the needle and prevent accidental poking of oneself. Such systems require removal of the needle guard to allow the user to view the insulin droplet form at the tip of the needle during the priming sequence of the pump. Current infusion systems do not provide a noticeably clear method to observe completion of priming without straining the eyesight and/or compromising the safety of the user.
  • BRIEF SUMMARY OF THE INVENTION
  • Embodiments of the present invention include a priming detection system and method for clear visual confirmation that a component of an infusion system is primed with an infusion fluid, which obviate for practical purposes, the above mentioned limitations.
  • According to an embodiment of the invention, the infusion system includes at least one reactive element to react with a fluid to be delivered into an individual's body. In embodiments, the reactive element reacts with the fluid or a component within the fluid when the fluid contacts the reactive element to produce a color change. The color change indicates that the component of the infusion system is primed with the fluid. In embodiments, the delivered fluid can be a therapeutic agent such as insulin or any other suitable medicament.
  • In embodiments, the system can further include a delivery element, such as a cannula or needle. The delivery element can have a proximal end and a distal end. The distal end of the delivery element can be configured to penetrate the individual's body and the proximal end of the delivery element can be directly or indirectly connected to the delivery device, to provide fluid communication between the delivery device and the individual's body so that the fluid can travel from the delivery device through the delivery element into the individual's body. In some embodiments, the reactive element is deposited on or incorporated in at least a portion of the delivery element.
  • According to another embodiment of the invention, the system further includes a guard element to at least partially surround or cover at least a portion of the delivery element. In some embodiments, the guard element includes at least one reactive element that reacts with the fluid exiting from the delivery element to produce a color change to indicate that the delivery element is primed with the fluid. In some embodiments, the guard element has an interior surface and an exterior surface and the reactive element is deposited on at least a portion of the interior surface of the guard element. In alternative embodiments, the reactive element can be incorporated into the material comprising the guard element.
  • In embodiments, the infusion system further includes a device for delivering the fluid into the individual's body. The delivery device can be an infusion pump, an infusion set, or another suitable fluid delivery device or fluid source. In some embodiments, the infusion pump is coupled to the delivery element. In further embodiments, the infusion set is coupled to the delivery element. In yet further embodiments, the system can include a tube coupled between an infusion set and an infusion pump, and/or between the delivery element and the delivery device, such as an infusion set or infusion pump. In embodiments including the tube, at least one reactive element can be deposited within at least a portion of the tube.
  • In embodiments, at least one reactive element can be applied to or incorporated in one or more components of the infusion system. In further embodiments, at least one reactive element is encapsulated in micro-spheres. In yet further embodiments, at least one reactive element is a component of a coating.
  • In one particular embodiment, the invention is a fluid detection system having at least one reactive element to indicate a component of an infusion system is primed with a fluid to be delivered into an individual's body. The fluid detection system comprises a delivery element having a proximal end and a distal end, the distal end configured to penetrate the individual's body and the proximal end coupled to a fluid source. For example, the fluid source can be an infusion set and/or an infusion pump. In embodiments, the fluid detection system further includes a guard element having a body that surrounds at least a portion of the delivery element. The guard element includes at least one reactive element that reacts with the fluid exiting from the distal end of the delivery element to produce a color change to indicate that the delivery element is primed with the fluid.
  • In embodiments, at least one reactive element is a liquid-activated dye to produce the color change when the fluid contacts the dye. For example, in some embodiments the liquid activated dye is a reversible or irreversible hydrochromatic or hydrochromic ink or dye. In further embodiments, at least one reactive element includes a chemical that reacts with at least one component within the fluid to produce the color change. For example, in some embodiments, at least one reactive element contains at least 4-amino-antipyrine and potassium ferricyanide. In alternative embodiments, at least one reactive element contains at least 4-amino-antipyrine, potassium ferricyanide and horse radish peroxidase (HRP). In another embodiment, at least one reactive element contains at least ninhydrin. In yet another embodiment, at least one reactive element contains at least Coomassie Brilliant Blue. In a further embodiment, at least one reactive element contains dithizone.
  • Various methods for determining when a component of an infusion system is primed with a fluid to be delivered into an individual's body can be ascertained from the description of embodiments of the invention herein. In one embodiment, the method comprises: providing the fluid and a device for delivering the fluid into the individual's body; providing the delivery element having a proximal end and a distal end, the distal end configured to penetrate the individual's body and the proximal end connected to the delivery device; providing a guard element to cover at least the distal end of the delivery element; depositing at least one reactive element that reacts with the fluid on the guard element; and producing and/or observing a color change when the fluid exiting from the distal end of the delivery element reacts with at least one reactive element on the guard element. The color change indicates that the delivery element is primed with the fluid.
  • Other features and advantages of the invention will become apparent from the following detailed description, taken in conjunction with the accompanying drawings which illustrate, by way of example, various features of embodiments of the invention.
  • BRIEF DESCRIPTION OF SEVERAL VIEWS OF THE DRAWINGS
  • A detailed description of embodiments of the invention will be made with reference to the accompanying drawings, wherein like numerals designate corresponding parts in the several figures.
  • FIG. 1 is a diagram showing an infusion set attached to a body, a flexible tube, and an infusion pump according to an embodiment of the present invention.
  • FIG. 2 is a perspective view of an infusion system according to an embodiment of the present invention.
  • FIG. 3A is a cross-sectional side view of an infusion set attached to a body tissue according to an embodiment of the present invention.
  • FIG. 3B is a perspective bottom view of the infusion set of FIG. 3A according to an embodiment of the present invention.
  • FIG. 3C is an enlarged front perspective view of a distal end of a delivery element having at least one reactive element deposited on at least a portion of the interior surface of the delivery element according to an embodiment of the present invention.
  • FIG. 3D is an enlarged front perspective view of a distal end of a delivery element having at least one reactive element deposited on at least a portion of the exterior surface of the delivery element according to an embodiment of the present invention.
  • FIG. 4 is a side view of an infusion pump attached to a body tissue, with a partial cut away of the pump, showing a cross-sectional view of a delivery element penetrating the body tissue according to an embodiment of the present invention.
  • FIG. 5 is a perspective bottom view of an infusion set and a perspective view of a guard element according to an embodiment of the present invention.
  • FIG. 6 is a perspective bottom view of an infusion set and a perspective view of a guard element covering a delivery element according to an embodiment of the present invention.
  • FIG. 7 is a perspective bottom view of an infusion set and a perspective view of a guard element covering a delivery element and showing a color change to indicate the delivery element is primed according to an embodiment of the present invention.
  • FIG. 8 is a perspective side view of a guard element having at least one reactive element deposited on the interior surface of the guard element according to an embodiment of the present invention.
  • FIG. 9 is a front view of an open end of a guard element having at least one reactive element deposited on at least a portion of the interior surface of the guard element according to an embodiment of the present invention.
  • FIG. 10 is a front view of an open end of a guard element having at least one reactive element incorporated in at least a portion of the guard element according to an embodiment of the present invention.
  • FIG. 11 is a perspective bottom view of an infusion set and a perspective view of a guard element surrounding a delivery element according to an embodiment of the present invention.
  • FIG. 12 is a perspective side view of a guard element having at least one reactive element deposited on the interior surface of the guard element according to an embodiment of the present invention.
  • FIG. 13 is a perspective bottom view of an infusion set and is a perspective view of a guard element surrounding a delivery element and showing a color change to indicate the delivery element is primed according to an embodiment of the present invention.
  • FIG. 14 is a diagram of a phenol molecule.
  • FIG. 15 is a diagram of a benzyl alcohol molecule.
  • FIG. 16 is a diagram of a 4-amino-antipyrine molecule.
  • FIG. 17 is a diagram of a potassium ferricyanide (K3Fe(CN)6 molecule.
  • FIG. 18 is a diagram of a bright blue chemical complex.
  • FIG. 19 is a diagram of a dithizone molecule.
  • DETAILED DESCRIPTION OF THE INVENTION
  • As shown in the drawings for purposes of illustration, the invention is embodied in an infusion system having a priming detection system designed to indicate the presence of a fluid that has been primed through a fluid path of the infusion system for delivery of the fluid into an individual's body at an infusion site. The priming detection system includes at least one reactive element that reacts with the fluid or a component of the fluid to produce a color change. The provided color change is a clear indication that a component of the infusion system has been primed with the infusion fluid and is ready for use. The infused fluid can be any therapeutic agent. In preferred embodiments the infused fluid is insulin. However, many other fluids may be administered through infusion such as, but not limited to, HIV drugs, drugs to treat pulmonary hypertension, iron chelation drugs, pain medications, anti-cancer treatments, vitamins, hormones, or the like. Preferred embodiments are for use with human beings; however, alternative embodiments may be used with animals or fluid flow applications where detection of small amounts of primed fluid is important.
  • An infusion system 10 utilizing the priming detection method can include any or all of the components shown in FIG. 1. An infusion pump 36 regulates the flow of fluid into an individual's body. In embodiments, shown in FIG. 1, the fluid flows from an infusion pump 36, through a flexible tube 40, through a delivery device such as, an infusion set 38, or the like, and through a delivery element (not shown) that is adhered to the individual's body 16. Infusion sets 38 that may be used as a delivery device are described in, but not limited to, U.S. Pat. Nos. 5,176,662; 5,257,980; 5,584,813; 6,056,718; and 6,461,329, which are hereby incorporated by reference. The infusion pump 36 may be of the type described in U.S. Pat. No. 4,562,751; 4,685,903; 5,080,653; 5,097,122; 5,505,709; 6,248,093; 6,554,798; and 6,752,785, which are hereby incorporated by reference. Alternatively, other infusion pumps 36 may be used for delivery of fluid 14 through an infusion set 38 or through a delivery element to an individual's body 16.
  • An example embodiment of a system 10 utilizing an infusion pump 36 is shown in FIG. 2. In such embodiments, the infusion pump 36 comprises a relatively compact pump housing 54 defining an elongated reservoir compartment 56 adapted to receive a reservoir 58 filled with a selected fluid, such as medication to be administered to an individual. The reservoir 58 may be a fillable or pre-filled reservoir, cartridge, syringe or the like. The reservoir 58 includes a barrel 60 for containing the fluid 14. In embodiments, a connector 66 serves as the interface between the reservoir 58 and the tube 40. The infusion pump 36 can include electronics and a motor to control movement of a plunger 62 for advancing the reservoir 58 to deliver the fluid 14 through a flexible tube 40 or the like into an individual's body.
  • In operation, the fluid 14 flows along a normal fluid path from reservoir 58 seated within the infusion pump 36, through the flexible tube 40, through a delivery device, such as the infusion set 38 or the like, and exits through a delivery element 20, such as a cannula, hollow needle, capillary, conduit, lumen, or the like, to deliver the fluid 14 to an infusion site 12. The infusion site 12 is at a location where a delivery element 20 penetrates an individual's body. In embodiments, one end of the delivery element 20 is attached to a delivery device and the other end, once primed with the infusion fluid 14, is inserted through an individual's skin 74 terminating in an individual's subcutaneous tissue 76 or another tissue such as, muscle, organ, inter-peritoneal, intra-peritoneal, or the like. The delivery element 20 establishes fluid communication between the delivery device and the individual's body. In some embodiments the delivery device is an infusion set 38 coupled to the delivery element 20. In alternative embodiments, the delivery device can be an infusion pump 36 or other fluid source directly attached to the surface of the individual's skin 74 and having a delivery element 20.
  • As shown in embodiments in FIGS. 3A and 3B, the delivery element 20, such as a cannula or the like, directs the fluid 14 from a cavity 72 inside the infusion set 38, through the individual's skin, and into the individual's subcutaneous tissue 76. The characteristics of delivery element 20, such as the length, inner and outer diameter, end configurations, and materials may vary depending on the tissue type that the delivery element 20 is inserted into, the volume and type of fluid 14 being infused, the configuration of the delivery device, and other parameters. The delivery element 20 can include a proximal end 22 and a distal end 24. The distal end 24 is configured to penetrate the individual's body and the proximal end 22 is connected or coupled to the delivery device, thus providing fluid communication between the delivery device and the individual's body. A tube 40 may be included to connect the infusion set 38 to the infusion pump 36 or other fluid source (not shown).
  • In alternative embodiments, the delivery device is an infusion pump 36 adhered directly to the individual's skin 74. In a particular embodiment, shown in FIG. 4, the infusion pump 36 has a cannula as the delivery element 20, to deliver fluid 14 directly from the infusion pump 36 through the individual's skin 74 to the subcutaneous tissue 76. In particular embodiments, other fluid conducting delivery elements 20 are used such as capillaries, conduits, lumens, or the like. The infusion pump 36 may be of the type described in U.S. Pat. Nos. 4,902,278; 5,785,688; 5,814,020; 5,848,991; 5,858,001; 7,569,050; 7,641,649; 7,686,787; and 7,699,833; or other small disposable pumps for delivery of fluid 14 through a delivery element 20 to an individual's body.
  • In some embodiments shown in FIGS. 2-4, the infusion pump 36 or infusion set 38 includes one or more pads 68 to attach the delivery device to the individual's skin 74. The pads 68 include an adhesive, and the pad 68 may be made of an adhesive, foam, glue, tape, a material coated with adhesive, or the like. As shown in the embodiments in FIG. 3A and FIG. 4, one side of the pad 68 can be attached to a base 70 of a delivery device, while the opposite side of the pad 68 can be adhered to an individual's skin 74. In other embodiments, the delivery device is held to the individual's skin 74 with a tape. In still other embodiments, both the adhesive of the pad 68 and tape are used to secure the infusion pump 36 or infusion set 38 to the individual's skin 74.
  • In the embodiments shown in FIGS. 5-13, a guard element 30 is included in the infusion system 10 and is configured to at least partially surround or cover at least a portion any of the above-described delivery elements 20, preferably the distal end of a delivery element 20. In some embodiments, the guard element 30 can be a needle guard, cap, lid, top, cover, or the like. The guard element 30 can have a first end 31 and a second end 33. In embodiments, at least one of the first end 31 and second end 33 of the guard element 30 can connect to the delivery device having the delivery element 20. In some embodiments, the guard element 30 and delivery device such as an infusion set can have mating or interfitting parts such as male and female threaded or snapping counterparts or the like to connect the guard element 30 to the delivery device. In an embodiment shown in FIG. 5, the guard element 30 comprises an elongated body 46 having a first end 31 that is an open end 50 to accept the delivery element 20 and a second end 33 that is a closed end 48 to enclose at least a portion of the delivery element 20. The guard element 30 can be made of a plastic or polymeric material, non-fiber material, fiber material or the like. The guard element 30 can be made of a rigid material to shield the user from the sharp distal end of a delivery element 20, such as a needle, and to further block contaminants from reaching the delivery element 20 to keep the delivery element 20 sterile.
  • In preferred embodiments, the fluid detection portion of the infusion system 10 that indicates when a component of the infusion system 10 is primed includes at least one reactive element 26 that changes color upon contact with the fluid 14 to be delivered to the user's body. The reactive element 26 or reactants may be deposited on the surfaces of the components, such as the guard element 30, the delivery element 20, the infusion set 38, and/or the tube 40, by different methods. In embodiments, the reactive element 26 can be sprayed, coated, deposited, layered or screened directly onto at least a portion of the surface of one or more of the components. In alternative embodiments, the reactive element 26 can be encapsulated in micro-spheres or included as a component of a material such as a gel, an absorbent material, foam, porous materials, starch granules, or the like, which are applied to at least a portion of the surface of one or more of the components.
  • In yet further embodiments, the reactive element 26 can be embedded in or otherwise incorporated in at least a portion of one or more components of the infusion system 10. The reactive element 26 can be applied to or incorporated into fabric materials, non-fabric materials, plastic or polymeric materials, fibrous materials, foam, porous materials, or the like, or other materials that wick away fluid to accelerate the reaction or make the resulting product of the reaction more visible and easily observable to the user. In embodiments, the reactive element can be embedded in pockets of such materials.
  • In further embodiments, the reactive element 26 can be sprayed, coated, deposited, layered or screened onto a layer that is applied to at least a portion of the surface of one or more of the components. The layer can be made of hydrogel, cloth, fibrous material, porous material, or other materials that wick away fluid to accelerate the reaction or make the resulting product of the reaction more visible. In further alternative embodiments, a label of any suitable flexible material may be prepared with the reactants on one or both sides of the label, and the label may be applied onto a surface of the guard element 30, the delivery element 20, the infusion set 38, and/or the tube 40.
  • As shown in embodiments in FIGS. 5 and 6, the guard element 30 covers the delivery element 20 such that the interior surface 32 of the guard element 30 faces the delivery element 20. Once the fluid 14 has traveled along the normal fluid path of the system from the delivery device and through the delivery element 20, the fluid 14 will exit the distal end of the delivery element 20 and come into contact with the guard element 30 covering the delivery element 20, and thus come into contact with the reactive element 26 coated on or incorporated in at least a portion of the guard element 30. As illustrated by the embodiment shown in FIG. 7, the reactive element 26 will produce a color change 28 that indicates that the system is primed through the delivery element 20 and is ready for insertion at the infusion site 12.
  • In embodiments shown in FIGS. 8 and 9, the guard element 30 has an interior surface 32 and an exterior surface 34, and the reactive element 26 is deposited or coated on a portion of or the entire interior surface 32 within the guard element 30. Alternatively, the reactive element 26 is deposited or coated in a layer that is applied to the interior surface 32 of the guard element 30. In an alternative embodiment shown in FIG. 10, the reactive element 26 is incorporated into the body of the guard element 30. For example, the guard element 30 can be made of a sintered plastic that absorbs liquid, a rigid fiber material, or other suitable material that can incorporate the reactive element 26. Further, the reactive element 26 may be deposited on a wicking material incorporated in or deposited on the interior surface 32 of the guard element to make the color change 28 easier to observe by the user. For example, the wicking material may draw the leaking fluid 14 toward the exterior surface of the guard element. In preferred embodiments, the guard element 30, or other component of the system utilizing the reactive element, is clear or transparent to increase visibility of the color change 28. In some embodiments, the guard element 30, or other component of the system utilizing the reactive element, may be comprised of a translucent material that allows color to be seen through the translucent material.
  • In alternative embodiments shown in FIGS. 11-13, the guard element 30 can have a body 46 with a first end 31 and a second end 33. As illustrated in the embodiments of FIGS. 11-13, the first end 31 and second end 33 can comprise two open ends 50 and 50′. In embodiments having two open ends 50 and 50′, the guard element 30 can surround the delivery element 20 and have a body 46 that extends past the delivery element 20. In embodiments, at least the first end 31 or the second end 33 of the guard element 30 can connect with a delivery device to surround the delivery element 20. For example, one open end 50′ of the guard element 30 and a portion of the delivery device such as an infusion set to which the open end 50′ connects can have mating or interfitting parts 88 such as male and female threaded or snapping counterparts or the like to connect the guard element 30 to the delivery device.
  • As shown in the embodiment in FIG. 11, the guard element 30 surrounds the delivery element 20 such that one end of the guard element 30 is attached to the delivery device and the interior surface 32 of the guard element 30 faces the delivery element 20. Once the fluid 14 has traveled along the normal fluid path of the system from the delivery device and through the delivery element 20, the fluid 14 will exit the distal end of the delivery element 20 and come into contact with the guard element 30 surrounding the delivery element 20, and thus come into contact with the reactive element 26 coated on or incorporated in at least a portion of the guard element 30. For example, the fluid 14 may drip down or to the side of the delivery element 20 to come into contact with at least a portion of the interior surface 32 of the body 46 of the guard element 30. As illustrated by the embodiment shown in FIG. 13, the reactive element 26 will produce a color change 28 that indicates that the system is primed through the delivery element 20. The user can then remove the guard element 30 from the delivery device, such as an infusion set 38, for insertion of the delivery element 20 into an individual's body.
  • In further alternative embodiments, the reactive element 26 may be deposited on at least a portion of the interior surface 23 of the infusion set 38 or interior surface 25 of the tube 40 that are wetted by the fluid 14 when the fluid 14 flows along the normal fluid path of the system. In yet further embodiments, the reactive element 26 can be deposited on at least a portion of the delivery element 20. For example, as shown in the embodiment in FIG. 3C, the reactive element 26 may be coated on an interior surface 27 of the delivery element 20. The entire interior surface 27 or a portion of the interior surface 27 of the delivery element 20 can be coated. In alternative embodiments, the reactive element 26 can be deposited at the exit on the edge of the distal end on the exterior surface 29 of the delivery element 20, as shown in an embodiment in FIG. 3D. The entire exterior surface 29 or a portion of the exterior surface 29 of the delivery element 20 can be coated. Embodiments utilizing the reactive element 26 that contact the fluid 14 to be infused along a fluid flow path of the system can use one or more reactive elements 26 that are safe for use in the individual's body so as not to harm the individual. As the fluid 14 flows along a normal path of the system from the tube 40, through the infusion set 38, and through the delivery element 20, one or all of the components utilizing the reactive element 26 will produce a color change 28 to indicate that the component is primed with the infusion fluid 14. In embodiments, the components of the system utilizing the color-changing reactive element may include other clear (optically transparent or translucent) materials for the individual to see through the component and observe the reaction.
  • In certain embodiments, the reactive element 26 can be a liquid-activated dye. The dye or ink can reversibly and irreversibly change from a first color to a second color when exposed to water. Upon contact with a fluid 14 or liquid, for example water or a fluid containing water, the dye can change from a first color to a second color when wet and remain the second color when dry, or change back to the first color when dry. The color can change from a dark color to a light color, a light color to a dark color, become transparent, or change from and to any color of the rainbow and shades in between, including white and black. As non-limiting examples, the liquid-activated dyes can be reversible or irreversible hydrochromatic or hydrochromic inks or coatings or the like. The first and second colors can be adjusted based on the hydrochromatic or hydrochromic molecules used in the dyes that are known to persons having ordinary skill in the art.
  • In embodiments, the reactive dye can react with at least one component within the fluid 14. For example, in embodiments where the fluid 14 to be delivered into an individual's body includes a protein, such as an insulin formulation, other reactive elements may be used to produce a color change 28. In particular embodiments, either ninhydrin or Coomassie Brilliant Blue reacts with the protein in the fluid 14 resulting in a brightly colored product. Other color-changing chemicals or dyes specific to the infused fluid 14 or a known component of the infused fluid 14, such as a protein, hormone, or other like component, can be used. In some embodiments, the at least one reactive element 26 can be a colorimetric protein assay reagent or chemical that reacts with a component of the fluid 14 to be delivered. For example, the reagent can be a dye that binds to a protein or a portion of a protein complex such that the color change 28 is directly or indirectly associated with the bound dye. In addition to indicating presence of the fluid-containing protein, the color change 28 in such embodiments can indicate the amount or strength of the protein in the fluid 14.
  • In some embodiments of the present invention, the reactive element 20 includes a chemical that reacts with preservatives in the infusion fluid 14 to generate a highly visible, brightly colored, chemical complex. Most fluids designed for parenteral administration (and/or infusion) contain a preservative. The most commonly used preservatives are based either on a phenol system 78 or a benzyl alcohol system 80. Examples of these systems are shown in FIGS. 14 and 15 respectively. Thus, one approach to detecting the fluid is to trigger a chemical reaction that is observable by an individual when any of these preservatives are present in a fluid.
  • In embodiments, a material, for example a clear gel, containing 4-amino-antipyrine 82, shown in FIG. 16, and potassium ferricyanide 84 (K3Fe(CN)6), shown in FIG. 17, is deposited on at least a portion of the surface of a component of the system. When fluid 14 contacts the reactive element 26, the preservative in the parenteral fluid reacts with the 4-amino-antipyrine 82 and potassium ferricyanide 84 in the material. The resulting product is a bright blue colored complex 86. Thus, the reactive elements, seen on, through, or around the edges of a component of the system, change from clear to bright blue, serving as a visual indicator to the individual. A drawing of the structure of the resulting bright blue colored complex 86 is shown in FIG. 18. The time required for detection may vary due to the concentrations of the reactants, 4-amino-antipyrine 82 and potassium ferricyanide 84, the concentration of the preservative in the fluid, the flow rate of the fluid, the rate at which the fluid comes in contact with the reactants, the method used to deposit the chemicals, the temperature, and the presence of contaminants. In alternative embodiments, the clear gel may be some other color, such as white, cream, off white, or the like, or a contrasting color to make the color change 28 noticeable. In other embodiments, the colored product is a different color, such as red, yellow, orange, pink, green, purple, or the like.
  • In alternative embodiments, an enzymatic system is used to amplify the chemical color change 28 signal. An enzyme, such as horse radish peroxidase (HRP), is added to the material containing 4-aminoantipyrine 82 and potassium ferricyanide 84. When a fluid 14 reaches the enzyme, water in the fluid 14 dissolves the HRP. The HRP then acts as a catalyst to, in essence, create an enzymatic amplification of the signal. Again, a deep blue colored complex 86 is formed due to the phenol 78 or benzyl alcohol 80 preservatives in the fluid 14 reacting with 4-aminoantipyrine 82 and potassium ferricyanide 84. The advantage of the HRP system is that only very small amounts of the fluid 14 need to be present to be detected. In alternative embodiments, the time required to detect the fluid 14 can vary depending on the concentration of HRP present in the gel, the concentration of the reactants 4-aminoantipyrine 82 and potassium ferricyanide 84, the method used to deposit the chemicals, the rate that the fluid 14 spreads and comes in contact with the reactants, the temperature, and the concentration of contaminates. The catalysts described above, which amplify the color change 28 from the chemical reaction, may also be deposited on a surface of a component of the system, such as the guard element 30, tubing 40, infusion set 38, or delivery element 20 of the system 10.
  • In another embodiment of the present invention, the reactive element 20 includes a chemical that reacts with zinc in an infusion fluid 14 to generate a color change. A drawing of the structure of an example molecule, dithizone 90, is shown in FIG. 19. Thus, one approach to detecting the fluid is to trigger a chemical reaction that is observable by an individual when zinc is present in a fluid. As a non-limiting example, the infusion fluid 14 can be insulin. Insulin formulations can include zinc that will react with the dithizone molecule 90 to produce a color change. Dithizone 90 can be incorporated in or deposited, coated, or the like, on a component of the infusion system 10 to indicate the component is primed.
  • In further alternative embodiments, the reactive elements 20 such as dithizone 90, 4-aminoantipyrine 82 and/or potassium ferricyanide 84 are encapsulated in micro-spheres. In particular embodiments, the micro-spheres dissolve in the presence of an ingredient contained in the infused fluid 14, such as water, alcohol, insulin or the like, which then sets the reactants free to react with the preservative in the fluid 14 as described above. Additional embodiments include HRP encapsulated in micro-spheres along with 4-aminoantipyrine 82 and potassium ferricyanide 84. In other embodiments, different methods are employed. These methods include applying the reactive elements with starch granules, depositing them in pockets formed in a component of the system, such as the guard element 30, encapsulating them and mixing them with a gel, embedding them into a component of the system, or the like.
  • Different methods for determining when a component of an infusion system is primed with a fluid to be delivered into an individual's body can be ascertained from the aforementioned embodiments of the invention described herein. For example, in one embodiment, the method comprises: providing the fluid and a device for delivering the fluid into the individual's body; providing the delivery element having a proximal end and a distal end, the distal end configured to penetrate the individual's body and the proximal end connected to the delivery device; providing a guard element to cover at least the distal end of the delivery element; depositing at least one reactive element that reacts with the fluid on the guard element; and producing and/or observing a color change when the fluid exiting from the distal end of the delivery element reacts with the at least one reactive element, thereby indicating that the delivery element is primed with the fluid.
  • While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. The accompanying claims are intended to cover such modifications as would fall within the true scope and spirit of the present invention. The presently disclosed embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims, rather than the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

Claims (20)

What is claimed is:
1. An infusion system having at least one reactive element to indicate a component of the infusion system is primed with a fluid to be delivered into an individual's body, the infusion system comprising:
a device for delivering the fluid into the individual's body;
a delivery element having a proximal end and a distal end, the distal end configured to penetrate the individual's body and the proximal end connected to the delivery device, to provide fluid communication between the delivery device and the individual's body; and
the at least one reactive element reacts with the fluid when the fluid contacts the at least one reactive element to produce a color change, wherein the color change indicates that the component of the infusion system is primed with the fluid.
2. The infusion system of claim 1, further including a guard element to cover at least a portion of the delivery element, the guard element including the at least one reactive element that reacts with the fluid exiting from the delivery element to produce the color change to indicate that the delivery element is primed with the fluid.
3. The infusion system of claim 2, the guard element having an interior surface and an exterior surface, wherein the at least one reactive element is deposited on at least a portion of the interior surface of the guard element.
4. The infusion system of claim 1, wherein the device is an infusion pump.
5. The infusion system of claim 4, the infusion system further including an infusion set coupled to the delivery element; and
a tube coupled between the infusion set and the infusion pump.
6. The infusion system of claim 5, wherein the at least one reactive element is deposited within at least a portion of the tube.
7. The infusion system of claim 1, wherein the at least one reactive element is deposited on at least a portion of the delivery element.
8. The infusion system of claim 1, wherein the at least one reactive element includes a liquid-activated dye to produce the color change.
9. The infusion system of claim 1, wherein the at least one reactive element includes a chemical that reacts with at least one component within the fluid to produce the color change.
10. The infusion system of claim 1, wherein the at least one reactive element contains at least 4-amino-antipyrine and potassium ferricyanide.
11. The infusion system of claim 1, wherein the at least one reactive element contains at least 4-amino-antipyrine, potassium ferricyanide and horse radish peroxidase (HRP).
12. The infusion system of claim 1, wherein the at least one reactive element contains at least ninhydrin.
13. The infusion system of claim 1, wherein the at least one reactive element contains at least Coomassie Brilliant Blue.
14. The infusion system of claim 1, wherein the at least one reactive element contains a hydrochromatic molecule.
15. The infusion system of claim 1, wherein the at least one reactive element contains at least dithizone.
16. The infusion system of claim 1, wherein the fluid is a therapeutic agent.
17. A method for determining when a delivery element of an infusion system is primed with a fluid to be delivered into an individual's body, the method comprising:
providing the fluid and a device for delivering the fluid into the individual's body;
providing the delivery element having a proximal end and a distal end, the distal end configured to penetrate the individual's body and the proximal end connected to the delivery device;
providing a guard element to cover at least the distal end of the delivery element;
depositing at least one reactive element that reacts with the fluid on at least a portion of the guard element; and
producing a color change when the fluid exiting from the distal end of the delivery element reacts with the at least one reactive element, thereby indicating that the delivery element is primed with the fluid.
18. An fluid detection system having at least one reactive element to indicate a component of an infusion system is primed with a fluid to be delivered into an individual's body, the fluid detection system comprising:
a delivery element having a proximal end and a distal end, the distal end configured to penetrate the individual's body and the proximal end coupled to a fluid source; and
a guard element configured to surround at least a portion of the delivery element, the guard element including the at least one reactive element that reacts with the fluid exiting from the distal end of the delivery element to produce a color change to indicate that the delivery element is primed with the fluid.
19. The fluid detection system of claim 18, further including a device for delivering the fluid into the individual's body.
20. The fluid detection system of claim 19, the guard element having a first end and a second end, wherein at least one of the first end and the second end is connected to the device.
US14/246,982 2014-04-07 2014-04-07 Priming detection system and method of using the same Active 2034-08-03 US9707336B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/246,982 US9707336B2 (en) 2014-04-07 2014-04-07 Priming detection system and method of using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/246,982 US9707336B2 (en) 2014-04-07 2014-04-07 Priming detection system and method of using the same

Publications (2)

Publication Number Publication Date
US20150283321A1 true US20150283321A1 (en) 2015-10-08
US9707336B2 US9707336B2 (en) 2017-07-18

Family

ID=54208838

Family Applications (1)

Application Number Title Priority Date Filing Date
US14/246,982 Active 2034-08-03 US9707336B2 (en) 2014-04-07 2014-04-07 Priming detection system and method of using the same

Country Status (1)

Country Link
US (1) US9707336B2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9387151B2 (en) 2013-08-20 2016-07-12 Anutra Medical, Inc. Syringe fill system and method
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD774182S1 (en) * 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
WO2018195298A1 (en) 2017-04-20 2018-10-25 Becton, Dickinson And Company Infusion set with leakage indicator
USD843563S1 (en) * 2015-06-22 2019-03-19 Novartis Ag Injector and insert for an injector
CN112041019A (en) * 2018-04-27 2020-12-04 株式会社以和洋行 End cap for liquid drug injection tube
WO2022047199A1 (en) * 2020-08-28 2022-03-03 Capillary Biomedical, Inc. Insulin infusion set

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3471796B1 (en) 2016-06-16 2023-09-13 Smiths Medical ASD, Inc. Assemblies and methods for infusion pump system administration sets
US10426896B2 (en) 2016-09-27 2019-10-01 Bigfoot Biomedical, Inc. Medicine injection and disease management systems, devices, and methods
CA3037432A1 (en) 2016-12-12 2018-06-21 Bigfoot Biomedical, Inc. Alarms and alerts for medication delivery devices and related systems and methods
USD836769S1 (en) 2016-12-12 2018-12-25 Bigfoot Biomedical, Inc. Insulin delivery controller
USD839294S1 (en) 2017-06-16 2019-01-29 Bigfoot Biomedical, Inc. Display screen with graphical user interface for closed-loop medication delivery
US11389088B2 (en) 2017-07-13 2022-07-19 Bigfoot Biomedical, Inc. Multi-scale display of blood glucose information
AU2018302257A1 (en) 2017-07-19 2020-01-30 Smiths Medical Asd, Inc. Housing arrangements for infusion pumps
USD863343S1 (en) 2017-09-27 2019-10-15 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4114617A (en) * 1977-02-28 1978-09-19 Turner Thomas D Apparatus for infusion of a measured volume of blood
US5147309A (en) * 1991-10-22 1992-09-15 Biosafety Systems, Inc. Apparatus for priming a hypodermic needle with hazardous fluid
US5855896A (en) * 1995-10-02 1999-01-05 Lim; Min H. Color changing composition and method for coating said composition on acupuncture needles, hypodermic syringes and other needles used in medical applications
US5958404A (en) * 1994-04-13 1999-09-28 Research Corporation Technologies, Inc. Treatment methods for disease using co-localized cells and Sertoli cells obtained from a cell line
US6059758A (en) * 1997-10-15 2000-05-09 Merit Medical Systems, Inc. Prophylactic sheath for protecting and storing different types of medical needles
US6461329B1 (en) * 2000-03-13 2002-10-08 Medtronic Minimed, Inc. Infusion site leak detection system and method of using the same
US20080051714A1 (en) * 2006-08-23 2008-02-28 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US20080118397A1 (en) * 2005-01-27 2008-05-22 Slowey Paul D Specimen sample collection device and test system
US20100190251A1 (en) * 2008-10-23 2010-07-29 HeeSuk KONG Method for the differentiation of human adult stem cells into insulin-secreting cells
US20110071492A1 (en) * 2009-09-18 2011-03-24 Becton, Dickinson And Company Hub assembly having a hidden needle for a drug delivery pen
US20140374353A1 (en) * 2013-06-25 2014-12-25 Fresenius Medical Care Holdings, Inc. Vial Spiking Assemblies and Related Methods

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338157B1 (en) 1992-09-09 1999-11-02 Sims Deltec Inc Systems and methods for communicating with ambulat
US4755173A (en) 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
US5307263A (en) 1992-11-17 1994-04-26 Raya Systems, Inc. Modular microprocessor-based health monitoring system
US5832448A (en) 1996-10-16 1998-11-03 Health Hero Network Multiple patient monitoring system for proactive health management
US5956501A (en) 1997-01-10 1999-09-21 Health Hero Network, Inc. Disease simulation system and method
US5545143A (en) 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
DK25793A (en) 1993-03-09 1994-09-10 Pharma Plast Int As Infusion set for intermittent or continuous administration of a therapeutic agent
US5536249A (en) 1994-03-09 1996-07-16 Visionary Medical Products, Inc. Pen-type injector with a microprocessor and blood characteristic monitor
US5391250A (en) 1994-03-15 1995-02-21 Minimed Inc. Method of fabricating thin film sensors
IE72524B1 (en) 1994-11-04 1997-04-23 Elan Med Tech Analyte-controlled liquid delivery device and analyte monitor
US5665065A (en) 1995-05-26 1997-09-09 Minimed Inc. Medication infusion device with blood glucose data input
DE69633573T2 (en) 1995-11-22 2005-10-06 Medtronic MiniMed, Inc., Northridge DETECTION OF BIOLOGICAL MOLECULES USING CHEMICAL AMPLIFICATION AND OPTICAL SENSOR
US6766183B2 (en) 1995-11-22 2004-07-20 Medtronic Minimed, Inc. Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers
US6607509B2 (en) 1997-12-31 2003-08-19 Medtronic Minimed, Inc. Insertion device for an insertion set and method of using the same
DE19717107B4 (en) 1997-04-23 2005-06-23 Disetronic Licensing Ag System of container and drive device for a piston, which is held in the container containing a drug fluid
US6186982B1 (en) 1998-05-05 2001-02-13 Elan Corporation, Plc Subcutaneous drug delivery device with improved filling system
US5954643A (en) 1997-06-09 1999-09-21 Minimid Inc. Insertion set for a transcutaneous sensor
US6558351B1 (en) 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US7647237B2 (en) 1998-04-29 2010-01-12 Minimed, Inc. Communication station and software for interfacing with an infusion pump, analyte monitor, analyte meter, or the like
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6736797B1 (en) 1998-06-19 2004-05-18 Unomedical A/S Subcutaneous infusion set
US6355021B1 (en) 1998-07-14 2002-03-12 Maersk Medical A/S Medical puncturing device
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US6248067B1 (en) 1999-02-05 2001-06-19 Minimed Inc. Analyte sensor and holter-type monitor system and method of using the same
US6558320B1 (en) 2000-01-20 2003-05-06 Medtronic Minimed, Inc. Handheld personal data assistant (PDA) with a medical device and method of using the same
JP4469504B2 (en) 1998-10-08 2010-05-26 メドトロニック ミニメド インコーポレイテッド Remote trait monitor system
EP2223713A3 (en) 1998-10-29 2015-02-18 Medtronic MiniMed, Inc. Connection interface between a reservoir and an infusion pump
US7193521B2 (en) 1998-10-29 2007-03-20 Medtronic Minimed, Inc. Method and apparatus for detecting errors, fluid pressure, and occlusions in an ambulatory infusion pump
US6248093B1 (en) 1998-10-29 2001-06-19 Minimed Inc. Compact pump drive system
US7806886B2 (en) 1999-06-03 2010-10-05 Medtronic Minimed, Inc. Apparatus and method for controlling insulin infusion with state variable feedback
US6453956B2 (en) 1999-11-05 2002-09-24 Medtronic Minimed, Inc. Needle safe transfer guard
US7003336B2 (en) 2000-02-10 2006-02-21 Medtronic Minimed, Inc. Analyte sensor method of making the same
US7890295B2 (en) 2000-02-23 2011-02-15 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US6895263B2 (en) 2000-02-23 2005-05-17 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US20010041869A1 (en) 2000-03-23 2001-11-15 Causey James D. Control tabs for infusion devices and methods of using the same
CA2771723C (en) 2000-09-08 2016-03-29 Insulet Corporation Devices, systems and methods for patient infusion
CN1556716A (en) 2001-02-22 2004-12-22 ���Ͽع����޹�˾ Modular infusion device and method
EP3210637B1 (en) 2001-04-06 2021-01-27 F. Hoffmann-La Roche AG Infusion set
US20020071225A1 (en) 2001-04-19 2002-06-13 Minimed Inc. Direct current motor safety circuits for fluid delivery systems
US6544212B2 (en) 2001-07-31 2003-04-08 Roche Diagnostics Corporation Diabetes management system
US7399277B2 (en) 2001-12-27 2008-07-15 Medtronic Minimed, Inc. System for monitoring physiological characteristics
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7041082B2 (en) 2002-02-28 2006-05-09 Smiths Medical Md, Inc. Syringe pump control systems and methods
US6960192B1 (en) 2002-04-23 2005-11-01 Insulet Corporation Transcutaneous fluid delivery system
US7278983B2 (en) 2002-07-24 2007-10-09 Medtronic Minimed, Inc. Physiological monitoring device for controlling a medication infusion device
US20040068230A1 (en) 2002-07-24 2004-04-08 Medtronic Minimed, Inc. System for providing blood glucose measurements to an infusion device
US7488601B2 (en) 2003-06-20 2009-02-10 Roche Diagnostic Operations, Inc. System and method for determining an abused sensor during analyte measurement
US8282549B2 (en) 2003-12-09 2012-10-09 Dexcom, Inc. Signal processing for continuous analyte sensor
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US7699807B2 (en) 2003-11-10 2010-04-20 Smiths Medical Asd, Inc. Device and method for insertion of a cannula of an infusion device
GB0329161D0 (en) 2003-12-16 2004-01-21 Precisense As Reagant for detecting an analyte
GB0329849D0 (en) 2003-12-23 2004-01-28 Precisense As Fluorometers
US7344500B2 (en) 2004-07-27 2008-03-18 Medtronic Minimed, Inc. Sensing system with auxiliary display
US8313433B2 (en) 2004-08-06 2012-11-20 Medtronic Minimed, Inc. Medical data management system and process
US7468033B2 (en) 2004-09-08 2008-12-23 Medtronic Minimed, Inc. Blood contacting sensor
WO2006102412A2 (en) 2005-03-21 2006-09-28 Abbott Diabetes Care, Inc. Method and system for providing integrated medication infusion and analyte monitoring system
US8298172B2 (en) 2005-04-13 2012-10-30 Novo Nordisk A/S Medical skin mountable device and system
US9233203B2 (en) 2005-05-06 2016-01-12 Medtronic Minimed, Inc. Medical needles for damping motion
US20080097291A1 (en) 2006-08-23 2008-04-24 Hanson Ian B Infusion pumps and methods and delivery devices and methods with same
US8277415B2 (en) 2006-08-23 2012-10-02 Medtronic Minimed, Inc. Infusion medium delivery device and method with drive device for driving plunger in reservoir
US8137314B2 (en) 2006-08-23 2012-03-20 Medtronic Minimed, Inc. Infusion medium delivery device and method with compressible or curved reservoir or conduit
US7713240B2 (en) 2005-09-13 2010-05-11 Medtronic Minimed, Inc. Modular external infusion device
US8475408B2 (en) 2005-11-08 2013-07-02 Asante Solutions, Inc. Infusion pump system
US8114269B2 (en) 2005-12-30 2012-02-14 Medtronic Minimed, Inc. System and method for determining the point of hydration and proper time to apply potential to a glucose sensor
US7985330B2 (en) 2005-12-30 2011-07-26 Medtronic Minimed, Inc. Method and system for detecting age, hydration, and functional states of sensors using electrochemical impedance spectroscopy
US8114268B2 (en) 2005-12-30 2012-02-14 Medtronic Minimed, Inc. Method and system for remedying sensor malfunctions detected by electrochemical impedance spectroscopy
US7942844B2 (en) 2006-04-28 2011-05-17 Medtronic Minimed, Inc. Remote monitoring for networked fluid infusion systems
US7828764B2 (en) 2006-08-23 2010-11-09 Medtronic Minimed, Inc. Systems and methods allowing for reservoir filling and infusion medium delivery
US20080125700A1 (en) 2006-11-29 2008-05-29 Moberg Sheldon B Methods and apparatuses for detecting medical device acceleration, temperature, and humidity conditions
US7946985B2 (en) 2006-12-29 2011-05-24 Medtronic Minimed, Inc. Method and system for providing sensor redundancy
US20080269714A1 (en) 2007-04-25 2008-10-30 Medtronic Minimed, Inc. Closed loop/semi-closed loop therapy modification system
US8323250B2 (en) 2007-04-30 2012-12-04 Medtronic Minimed, Inc. Adhesive patch systems and methods
US7963954B2 (en) 2007-04-30 2011-06-21 Medtronic Minimed, Inc. Automated filling systems and methods
US8267921B2 (en) 2007-07-20 2012-09-18 Medingo Ltd. Manually operable portable infusion device
US20090270705A1 (en) 2008-04-28 2009-10-29 Medtronic Minimed, Inc. Automobile Physiological Monitoring System and Method for Using the Same
US8181849B2 (en) 2008-12-30 2012-05-22 Medtronic Minimed, Inc. Color detection system for detecting reservoir presence and content in device
US8308679B2 (en) 2009-12-30 2012-11-13 Medtronic Minimed, Inc. Alignment systems and methods

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4114617A (en) * 1977-02-28 1978-09-19 Turner Thomas D Apparatus for infusion of a measured volume of blood
US5147309A (en) * 1991-10-22 1992-09-15 Biosafety Systems, Inc. Apparatus for priming a hypodermic needle with hazardous fluid
US5958404A (en) * 1994-04-13 1999-09-28 Research Corporation Technologies, Inc. Treatment methods for disease using co-localized cells and Sertoli cells obtained from a cell line
US5855896A (en) * 1995-10-02 1999-01-05 Lim; Min H. Color changing composition and method for coating said composition on acupuncture needles, hypodermic syringes and other needles used in medical applications
US6059758A (en) * 1997-10-15 2000-05-09 Merit Medical Systems, Inc. Prophylactic sheath for protecting and storing different types of medical needles
US6461329B1 (en) * 2000-03-13 2002-10-08 Medtronic Minimed, Inc. Infusion site leak detection system and method of using the same
US20080118397A1 (en) * 2005-01-27 2008-05-22 Slowey Paul D Specimen sample collection device and test system
US20080051714A1 (en) * 2006-08-23 2008-02-28 Medtronic Minimed, Inc. Infusion medium delivery system, device and method with needle inserter and needle inserter device and method
US20100190251A1 (en) * 2008-10-23 2010-07-29 HeeSuk KONG Method for the differentiation of human adult stem cells into insulin-secreting cells
US20110071492A1 (en) * 2009-09-18 2011-03-24 Becton, Dickinson And Company Hub assembly having a hidden needle for a drug delivery pen
US20140374353A1 (en) * 2013-06-25 2014-12-25 Fresenius Medical Care Holdings, Inc. Vial Spiking Assemblies and Related Methods

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9387151B2 (en) 2013-08-20 2016-07-12 Anutra Medical, Inc. Syringe fill system and method
US9393177B2 (en) 2013-08-20 2016-07-19 Anutra Medical, Inc. Cassette assembly for syringe fill system
US9579257B2 (en) 2013-08-20 2017-02-28 Anutra Medical, Inc. Haptic feedback and audible output syringe
US10010482B2 (en) 2013-08-20 2018-07-03 Anutra Medical, Inc. Syringe fill system and method
US10010483B2 (en) 2013-08-20 2018-07-03 Anutra Medical, Inc. Cassette assembly for syringe fill system
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD774182S1 (en) * 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD843563S1 (en) * 2015-06-22 2019-03-19 Novartis Ag Injector and insert for an injector
WO2018195298A1 (en) 2017-04-20 2018-10-25 Becton, Dickinson And Company Infusion set with leakage indicator
JP2020517319A (en) * 2017-04-20 2020-06-18 ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company Infusion set with leak indicator
EP3612251A4 (en) * 2017-04-20 2021-01-13 Becton, Dickinson and Company Infusion set with leakage indicator
US11273258B2 (en) 2017-04-20 2022-03-15 Becton, Dickinson And Company Infusion set with leakage indicator
JP7105800B2 (en) 2017-04-20 2022-07-25 ベクトン・ディキンソン・アンド・カンパニー Infusion set with leak indicator
CN112041019A (en) * 2018-04-27 2020-12-04 株式会社以和洋行 End cap for liquid drug injection tube
US11878139B2 (en) 2018-04-27 2024-01-23 E-Wha Meditech Inc. Endcap for liquid medicine-injecting tube
WO2022047199A1 (en) * 2020-08-28 2022-03-03 Capillary Biomedical, Inc. Insulin infusion set

Also Published As

Publication number Publication date
US9707336B2 (en) 2017-07-18

Similar Documents

Publication Publication Date Title
US9707336B2 (en) Priming detection system and method of using the same
US6752785B2 (en) Leak detection system and method of using the same
JP6821564B2 (en) Needle assembly with flashback indicator and related methods
JP6290982B2 (en) Night basic dosing device
US10773020B2 (en) Infusion site leak detection device
US20090163874A1 (en) Skin-Mountable Device in Packaging Comprising Coated Seal Member
US20090254041A1 (en) Assembly Comprising Skin-Mountable Device and Packaging Therefore
US20040116865A1 (en) Needle insertion device
CN110520174B (en) Infusion device with leak indicator
JP2005537893A5 (en)
US6156008A (en) Device for avoiding subdermal hematomas from an injection
US20200306444A1 (en) Fluid delivery device with leak detection
JP2006501893A (en) Needle insertion device
US20230140353A1 (en) Subcutaneous device with leak prevention

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDTRONIC MINIMED, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DANG, KIEM H.;HALILI, EDGARDO C.;SIGNING DATES FROM 20140504 TO 20140523;REEL/FRAME:032958/0993

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4